The Administrative Core provides the infrastructure for and coordinates all activities of the MPD Research Consortium (MPD-RC). Key functions include organizational management and communication, resource allocation and management (personnel, funds,equlpment, and supplies), organization of all internal and external advisory boards, scientific and clinical trials oversight to assure regulatory cornpliarice and procedural implementation, and exetmal liaison to appropriate governmental agencies.
The specific aims of the Administrative are: 1) coordinate activities of all projects, and cores belonging to the MPD-RC;2) schedule and provide optimal staff support for all MPD-RC committees and boards and establish and staff new committees when necessary;3) assure that the use of both human subjects and animal subjects is monitored in compliance with NIH regulations for research using human subjects and animals;4) administer and oversee all budgets;5) liaison to the NCI for all matters pertaining to the MPD-RC;6) submit all applications for use of Investigational New Drugs (IND) to the U.S. Federal Drug Administration;7) report all adverse events experienced by patients participating in clinical trials to investigators, participating instituions and appropriate regulatory agencies;8) develop and negotiate contracts with pharmaceutical companies to gain access to drugs to be administered in clinical trials and obtain partial support from pharmaceutical companies for the performance of these trials;9) prepare and provide yearly progress reports to the NCI.
The Administrative Core is a critical resource which coordinates the activities of the 6 projects and other cores which comprise the MPD-RC. This core provides an organizational foundation which permits the investigators who are located at multiple geographic sites across 9 time zones to closely and effectively interact.
|Gilles, Laure; Arslan, Ahmet Dirim; Marinaccio, Christian et al. (2017) Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 127:1316-1320|
|Varricchio, Lilian; Falchi, Mario; Dall'Ora, Massimiliano et al. (2017) Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function. Front Cell Dev Biol 5:96|
|Zingariello, M; Sancillo, L; Martelli, F et al. (2017) The thrombopoietin/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J 7:e572|
|Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2017) The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp Hematol 50:53-76|
|Lanikova, Lucie; Reading, N Scott; Hu, Hao et al. (2017) Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer. Oncotarget 8:11739-11747|
|Sergueeva, Adelina; Miasnikova, Galina; Shah, Binal N et al. (2017) Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. Haematologica 102:e166-e169|
|Wang, Linghua; Wheeler, David A; Prchal, Josef T (2016) Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol 44:644-52|
|Klionsky, Daniel J (see original citation for additional authors) (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222|
|Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12|
|Spangrude, Gerald J; Lewandowski, Daniel; Martelli, Fabrizio et al. (2016) P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells 34:67-82|
Showing the most recent 10 out of 181 publications